2015 - 17
Mr. Nilesh Gupta
Managing Director & Executive Director to the Board Lupin Limited
Nilesh Gupta is the Managing Director of Lupin Limited. A Chemical Engineer from the University Department of Chemical Technology, Mumbai, and an MBA from the Wharton School, USA, he has been responsible for transforming Lupin's research programs, strengthening the Company's global manufacturing operations and quality functions and is a key part of the top team formulating and executing the core strategy that has helped Lupin emerge as a global generic and specialty pharmaceutical major.
Nilesh joined Lupin in 1996 and has headed various responsibilities in the past such as research, supply chain, manufacturing, quality and regulatory. After being appointed the Managing Director of Lupin in 2013, he continues to directly oversee the Company's business in Asia Pacific, India, API & Biotech in addition to heading Research, Technical Operations, Procurement, Regulatory and QA.
Mr. Glenn Saldanha
Vice President -Indian Pharmaceutical Alliance and Chairman & Managing Director - Glenmark Pharmaceuticals Ltd.
As the Chairman and Managing Director of Glenmark Pharmaceuticals Ltd., Glenn Saldanha oversees the entire operations of the organization.
In 1998, Glenn decided to give up a promising career in the US and return back to India with an ambition to create something unique. Recognizing the enormous opportunity in the Indian Pharmaceutical Industry, he joined Glenmark and took over the operations as the CEO. During his tenure, Glenmark has been transformed into a truly global research-led organization with revenue of approximately USD 1.1 billion dollars and offices in more than 20 countries worldwide. Glenmark's branded generics presence is spread across five regions viz. Asia including India, Europe, Africa, Latin America and RCIS. Glenmark has also established itself among the top 25 generics companies in the US and has built a sizeable API business in a short period. Presently, over 70% of Glenmark's total turnover comes from the overseas operations.
During his tenure, the biggest achievement for Glenmark has been its ability to discover best-in-class or first-in-class molecules for global development and unmet medical needs thus positioning Glenmark as a leader in drug discovery. Glenmark has managed to strike seven out licensing deals in innovative R&D with big pharmaceutical companies. Presently, Glenmark has a strong pipeline of seven molecules in various stages of clinical and preclinical stages, all having potential in the range of USD 1 to 3 billion, if successfully commissioned. Glenn's vision is to discover, develop and take to market India's first innovative drug for the entire world.
Glenn holds a Bachelor's Degree in Pharmacy from Mumbai University and holds an MBA from Leonard Stern School of Business, New York University. Prior to Glenmark, he has worked with Eli Lily, USA and PricewaterhouseCoopers, USA.
In 2014 he was conferred with Best CEO: Pharma & Healthcare (mid-sized companies')' by Business Today. Also in the same year, he was among the ranking of 'Top 50 CEOs in India' by Entrepreneur Magazine. He was also conferred with the 'Swiss Ambassador's Award for Exceptional Innovation' - Embassy of Switzerland in 2012 and was among the Top 30 Youth Icons of India' 2012 by Hindustan Times.
Mr. Dilip G Shah
Vision Consulting Group
Mr. Dilip G. Shah graduated from the premier business school in India, the Indian Institute of Management (IIM), Ahmedabad. He has 50 years of varied experience in the pharmaceutical industry. He has addressed several WTO workshops on TRIPS, WIPO seminars on IPRs and Public Health, WHO meetings on Access to Medicines and several other international meetings and conferences. He was a Member of the official Indian Delegation to WTO Ministerial Conference in Cancun. He also appeared before the U.S. International Trade Commission (USITC) and testified in Investigation No.332-543 Hearing in Washington DC in 2014.
Currently, he is the Secretary-General of the Indian Pharmaceutical Alliance (www.ipa-india.org), Member of the Expert Review Committee on Access to Medicine (ATM) Index (www.atmindex.org); Member of the CPhI International Advisory Board; Member of the Board of Advisors of Pharmabiz.com (Weekly); and Member of Task Forces and Expert Groups constituted by the Government of India for accelerating growth of the Indian pharmaceutical industry. He was Chair of the International Generic Pharmaceutical Alliance (IGPA) for two terms (2005-07) and (2010-11).
Mr. Shah is an independent director on the Boards of Fresenius Kabi Oncology Ltd and Anuh Pharma Ltd and CEO of Vision Consulting Group (www.vision-india.com), a firm specialized in strategic planning. Before starting Vision in 1997, he was a Member of the Board of Directors of Pfizer-India for whom he worked for 30 years.